Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8691723 | 0.89 | HPGD (0.59) | CHRM3KMT2AMEN1KCNH2ALDH1A1 | |
| SCHEMBL25732839 | 0.83 | DRD3 (0.64) | POLBKCNA5DRD2HPGD | |
| SCHEMBL25238971 | 0.81 | HPGD (0.64) | KMT2AKDM4EALDH1A1KCNA5DRD2 | |
| SCHEMBL14366509 | 0.81 | KMT2A (0.71) | KMT2AMEN1KCNH2KDM4EALDH1A1 | |
| SCHEMBL7634958 | 0.81 | KMT2A (0.71) | KMT2AMEN1KCNH2KDM4EALDH1A1 | |
| SCHEMBL7824996 | 0.80 | HTT (0.61) | — | |
| SCHEMBL27577326 | 0.79 | CHRM3 (0.57) | CHRM3KMT2AMEN1ALDH1A1SIGMAR1 | |
| SCHEMBL18770805 | 0.79 | DRD2 (0.82) | KMT2AMEN1KCNH2KDM4EALDH1A1 | |
| SCHEMBL18199757 | 0.78 | CHRM3 (1.00) | CHRM3KMT2AMEN1DRD2 | |
| SCHEMBL31178357 | 0.78 | KMT2A (0.62) | KMT2AMEN1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | claimed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | CHRM3 1879/4885KMT2A 2748/4885MEN1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.